Yousif Capital Management LLC Cuts Stake in Illumina, Inc. $ILMN

Yousif Capital Management LLC decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 1.8% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 47,707 shares of the life sciences company’s stock after selling 879 shares during the period. Yousif Capital Management LLC’s holdings in Illumina were worth $4,552,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in ILMN. Corvex Management LP boosted its stake in shares of Illumina by 125.2% in the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock valued at $303,841,000 after purchasing an additional 2,129,449 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Illumina by 361.7% in the 1st quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company’s stock valued at $165,484,000 after purchasing an additional 1,662,093 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in shares of Illumina by 11,714.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,161,882 shares of the life sciences company’s stock valued at $92,184,000 after purchasing an additional 1,152,048 shares in the last quarter. Brown Advisory Inc. boosted its stake in shares of Illumina by 52.1% in the 1st quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company’s stock valued at $230,818,000 after purchasing an additional 996,589 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Illumina by 51.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,960,385 shares of the life sciences company’s stock valued at $155,537,000 after purchasing an additional 667,978 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 2.2%

NASDAQ:ILMN opened at $93.00 on Thursday. The company has a 50-day moving average price of $98.10 and a 200-day moving average price of $90.44. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The stock has a market cap of $14.29 billion, a price-to-earnings ratio of 11.77, a P/E/G ratio of 2.19 and a beta of 1.40.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period last year, the company posted $0.36 EPS. The company’s quarterly revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Barclays increased their price target on shares of Illumina from $90.00 to $95.00 and gave the company an “underweight” rating in a research report on Thursday, October 2nd. Evercore ISI dropped their price target on shares of Illumina from $135.00 to $132.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Citigroup cut shares of Illumina from a “hold” rating to a “strong sell” rating and dropped their price target for the company from $85.00 to $80.00 in a research report on Wednesday, July 9th. Finally, Robert W. Baird increased their price target on shares of Illumina from $84.00 to $105.00 and gave the company a “neutral” rating in a research report on Monday, July 28th. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina has a consensus rating of “Hold” and an average target price of $123.56.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.